Additional tyrosine kinase inhibitors have since become mainstays of non-small cell lung cancer (NSCLC) treatment, including erlotinib for patients with epidermal growth factor receptor (EGFR) mutations and crizotinib for those with anaplastic lymphoma kinase-positive (ALK+) disease [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.